GlassScriptPhysician profile
Rebecca Mcphail
NPI 1063968022
$8,601.47
in general payments reported to CMS, 2019-2025
45 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $2,046 · 2023: $2,641 · 2024: $1,881 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,039 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,038.58 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,086.75 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,058.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $808.55 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $800.03 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $494.78 | 2021-2025 | |
| Amgen INC. | $377.80 | 2024-2025 | Evenity, Tepezza, Repatha |
| Corcept Therapeutics | $353.24 | 2021-2025 | Korlym |
| Abbott Laboratories | $336.89 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $306.77 | 2022-2024 | Afrezza |
| Insulet Corporation | $266.21 | 2022-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.05 | 2021-2024 | Synjardy, Jardiance |
| Bigfoot Biomedical INC | $188.84 | 2023 | Unity Diabetes Management System |
| Ibsa Pharma INC. | $165.70 | 2021-2025 | Tirosint, Licart, Tirosint |
| Radius Health, INC. | $159.18 | 2021-2025 | Tymlos |
| Abbvie INC. | $149.69 | 2022-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $136.35 | 2021-2024 | |
| Dexcom, INC. | $129.16 | 2021-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $128.58 | 2021-2024 | Unithroid |
| Astellas Pharma US INC | $127.27 | 2023-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $121.58 | 2023-2024 | Dificid, Verquvo, Steglatro |
| Medtronic, INC. | $95.04 | 2024-2025 | Minimed 780g |
| Chiesi USA, INC. | $88.26 | 2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $86.76 | 2023-2025 | Yorvipath |
| Pfizer INC. | $79.98 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $74.02 | 2022-2023 | |
| Madrigal Pharmaceuticals | $73.56 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $70.95 | 2021-2024 | Farxiga |
| Recordati_rare_diseases_inc. | $67.28 | 2022-2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $66.82 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.10 | 2023-2024 | Cycloset, Xifaxan, Trulance |
| Inspire Medical Systems, INC. | $56.97 | 2024 | Inspire |
| Sequel Med Tech, LLC | $50.64 | 2025 | Twiist |
| Amarin Pharma, INC. | $43.93 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.33 | 2025 | Shingrix, Arexvy |
| Cequr Corporation | $31.79 | 2022-2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $26.88 | 2024 | Heplisav-B |
| Verity Pharmaceuticals INC. | $26.34 | 2025 | Tlando |
| Kyowa Kirin, INC. | $25.69 | 2022-2025 | |
| Csl Behring | $24.95 | 2025 | Hizentra |
| Actelion Pharmaceuticals US, INC. | $24.58 | 2024 | Opsumit, Uptravi |
| Horizon Therapeutics Plc | $22.60 | 2022 | |
| Exact Sciences Corporation | $19.00 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.73 | 2023 | Quviviq |
| Halozyme INC | $13.57 | 2023 | |
| Eusa Pharma (US) LLC | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Mcphail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.